Karyopharm Therapeutics (NASDAQ:KPTI) Downgraded by ValuEngine

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by research analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued on Monday, ValuEngine reports.

KPTI has been the subject of several other reports. JPMorgan Chase & Co. upgraded Karyopharm Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the company from $8.00 to $16.00 in a research note on Tuesday, July 23rd. Wedbush increased their target price on Karyopharm Therapeutics from $6.00 to $11.00 in a research note on Monday, July 8th. HC Wainwright reiterated a “buy” rating and set a $32.00 target price (up from $29.00) on shares of Karyopharm Therapeutics in a research note on Friday, July 5th. BidaskClub upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Zacks Investment Research cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, July 13th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. Karyopharm Therapeutics presently has a consensus rating of “Buy” and an average target price of $17.32.

Shares of Karyopharm Therapeutics stock traded down $0.13 on Monday, hitting $8.73. 1,338,292 shares of the company’s stock traded hands, compared to its average volume of 1,839,446. The firm has a market capitalization of $564.72 million, a PE ratio of -2.78 and a beta of 2.40. The company has a current ratio of 6.93, a quick ratio of 6.19 and a debt-to-equity ratio of 1.46. The business’s 50-day simple moving average is $8.03. Karyopharm Therapeutics has a 52-week low of $3.92 and a 52-week high of $21.71.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, August 6th. The company reported ($0.71) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.97) by $0.26. The company had revenue of $9.49 million during the quarter. Karyopharm Therapeutics had a negative return on equity of 154.75% and a negative net margin of 2,138.80%. As a group, equities research analysts predict that Karyopharm Therapeutics will post -3.65 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Envestnet Asset Management Inc. lifted its stake in Karyopharm Therapeutics by 12.4% during the second quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock worth $72,000 after purchasing an additional 1,319 shares during the last quarter. Legal & General Group Plc lifted its stake in Karyopharm Therapeutics by 31.3% during the fourth quarter. Legal & General Group Plc now owns 10,116 shares of the company’s stock worth $95,000 after purchasing an additional 2,411 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Karyopharm Therapeutics by 20.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the company’s stock worth $419,000 after purchasing an additional 3,400 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Karyopharm Therapeutics by 8.6% during the second quarter. Wells Fargo & Company MN now owns 60,384 shares of the company’s stock worth $361,000 after purchasing an additional 4,761 shares during the last quarter. Finally, Bank of Montreal Can bought a new position in Karyopharm Therapeutics during the second quarter worth $29,000. Hedge funds and other institutional investors own 83.86% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).

Recommended Story: Straddles

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.